| Outcome: PSAT score | ||
---|---|---|---|
Estimate | CI | p | |
Intercept | 2.58 | 1.36–3.80 |  < 0.001 |
Group: control | Â | Baseline | Â |
Group: intervention | 1.35 | 0.29–2.40 | 0.01 |
Year: 0 | Baseline | ||
 Year: 1 | 0.31 |  − 0.08–0.70 | 0.12 |
 Year: 2 | 0.34 |  − 0.00–0.68 | 0.05 |
Passive dosage: none | Baseline | ||
 Passive dosage: any |  − 0.31 |  − 0.82–0.20 | 0.23 |
 Active dosage |  − 0.06 |  − 0.44–0.31 | 0.73 |
 CDC rec. funding (%) | 0.01 | 0.01–0.02 | 0.001 |
 ALA score | 0.04 | 0.02–0.05 |  < 0.001 |
Program manager: vacant | Baseline | ||
 Program manager: < 1 year |  − 0.01 |  − 1.03–1.01 | 0.99 |
 Program manager: 1–3 years | 0.21 |  − 0.75–1.17 | 0.66 |
 Program manager: 3–5 years | 0.43 |  − 0.63–1.49 | 0.43 |
 Program manager: > 5 years | 0.36 |  − 0.63–1.34 | 0.47 |
  Group × passive dosage | 0.42 |  − 0.24–1.07 | 0.21 |
  Group × active dosage | 0.12 |  − 0.23–0.47 | 0.50 |
  Group × ALA score |  − 0.05 |  − 0.07 to − 0.02 | 0.00 |
Random effects and model statistics | |||
 σ2 | 0.15 | ||
 ICC | 0.4 | ||
 N | 23 | ||
 Observations | 69 | ||
 Marginal R2/conditional R2 | 0.49/0.70 |